{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:32:40Z","timestamp":1770255160197,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-03035-3","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:57:08Z","timestamp":1767841028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of non-dihydropyridine calcium channel blockers with beta blockers as treatment for atrial fibrillation: protocol for a systematic review with meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Tim","family":"Koldenhof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barzi","family":"Gareb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelle D.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thijmen S. A.","family":"Bergwerff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Tieleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2581-070X","authenticated-orcid":false,"given":"Michiel","family":"Rienstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"0","key":"3035_CR1","first-page":"174749301989787","volume":"0","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2020;0(0):1747493019897870.","journal-title":"Int J Stroke"},{"issue":"36","key":"3035_CR2","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314.","journal-title":"Eur Heart J"},{"issue":"10046","key":"3035_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(16)31258-2","volume":"388","author":"IC Van Gelder","year":"2016","unstructured":"Van Gelder IC, Rienstra M, Crijns HJGM, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016;388(10046):818\u201328.","journal-title":"Lancet"},{"issue":"15","key":"3035_CR4","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","volume":"362","author":"IC Van Gelder","year":"2010","unstructured":"Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363\u201373.","journal-title":"N Engl J Med"},{"key":"3035_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Bax JJ, Boriani G, Dan GA, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373\u2013498. Oxford University Press (OUP).","journal-title":"Eur Heart J"},{"issue":"4","key":"3035_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/europace\/euab200","volume":"24","author":"A Metzner","year":"2022","unstructured":"Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, et al. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial. Europace. 2022;24(4):552\u201364.","journal-title":"Europace"},{"issue":"2","key":"3035_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jemermed.2015.01.014","volume":"49","author":"C Fromm","year":"2015","unstructured":"Fromm C, Suau SJ, Cohen V, Likourezos A, Jellinek-Cohen S, Rose J, et al. Diltiazem vs. metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department. J Emerg Med. 2015;49(2):175\u201382.","journal-title":"J Emerg Med"},{"issue":"3","key":"3035_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jemermed.2022.07.014","volume":"63","author":"B Long","year":"2022","unstructured":"Long B, Keim SM, Gottlieb M, Stiell IG. What is the best agent for rate control of atrial fibrillation with rapid ventricular response? J Emerg Med. 2022;63(3):467\u201376.","journal-title":"J Emerg Med"},{"key":"3035_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ajem.2024.12.070","volume":"89","author":"TD Hintze","year":"2025","unstructured":"Hintze TD, Downing JV, Acquisto NM, Downton Mslis K, Yardi I, Moran M, et al. Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events. Am J Emerg Med. 2025;89:230\u201340. W.B. Saunders.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"3035_CR10","first-page":"e56560","volume":"16","author":"AH Mayow","year":"2024","unstructured":"Mayow AH, Sinha T, Ahmad M, Myint YK, Balaji S, Chaudhari SS, et al. Comparison of the effectiveness and safety of metoprolol and diltiazem in atrial fibrillation with rapid ventricular rate patients: a systematic review and meta-analysis. Cureus. 2024;16(3):e56560.","journal-title":"Cureus"},{"issue":"1","key":"3035_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):148\u201360.","journal-title":"Syst Rev"},{"issue":"4","key":"3035_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Antes G, Atkins D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"key":"3035_CR13","first-page":"372","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:372.","journal-title":"BMJ"},{"issue":"3","key":"3035_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","volume":"104","author":"WM Bramer","year":"2016","unstructured":"Bramer WM, Giustini D, De Jong GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240.","journal-title":"J Med Libr Assoc"},{"issue":"1","key":"3035_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1\u201310.","journal-title":"Syst Rev"},{"key":"3035_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. 2023.\u00a0https:\/\/training.cochrane.org\/handbook."},{"issue":"3","key":"3035_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"3035_CR18","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G OA. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. GRADE Work Gr. 2013.\u00a0https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"issue":"3","key":"3035_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/europace\/euab191","volume":"24","author":"T Koldenhof","year":"2022","unstructured":"Koldenhof T, Wijtvliet PEPJ, Pluymaekers NAHA, Rienstra M, Folkeringa RJ, Bronzwaer P, et al. Rate control drugs differ in the prevention of progression of atrial fibrillation. EP Europace. 2022;24(3):384\u20139.","journal-title":"EP Europace"},{"issue":"2","key":"3035_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.amjcard.2012.09.020","volume":"111","author":"SR Ulimoen","year":"2013","unstructured":"Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225\u201330.","journal-title":"Am J Cardiol"},{"issue":"8","key":"3035_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/eurheartj\/eht429","volume":"35","author":"SR Ulimoen","year":"2014","unstructured":"Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2014;35(8):517\u201323.","journal-title":"Eur Heart J"},{"key":"3035_CR22","doi-asserted-by":"crossref","unstructured":"Niforatos JD, Ehmann MR, Balhara KS, Hinson JS, Ramcharran L, Lobner K, et al. Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: a systematic review. Acad Emerg Med. 2023;30(2):124\u201332.","DOI":"10.1111\/acem.14618"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-03035-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:15:24Z","timestamp":1770207324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-025-03035-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3035"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-03035-3","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review does not require formal ethics approval because it is based on published studies. The result of this study will be submitted to a peer-reviewed journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This systematic review does not use any individual person\u2019s data and does not require consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TK, BG, MDS, TSAB, MR have nothing to declare in relation to this paper. RGT reports grants from Medtronic and Abbott, and personal fees from Boehringer Ingelheim, Bayer, and Pfizer\/Bristol Myers Squibb, and is co-inventor of the MyDiagnostick, not receiving royalties for the past 5\u00a0years, all outside the submitted work. MR reports consultancy fees from Bayer, Microport, InCarda Therapeutics to the institution, all outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}